Hemophilia A Clinical Trial
Official title:
Bone and Joint Health in an Adult Hemophilia Population
NCT number | NCT01460147 |
Other study ID # | 001001 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | October 30, 2011 |
Est. completion date | April 13, 2012 |
Verified date | April 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate bone mineral density in adult subjects with hemophilia versus a comparator population without hemophilia (non-hemophilia age- and gender-matched database) by using the following diagnostic means: dual-energy X-ray absorptiometry (DXA) scanning, clinical scales, quality of life (QOL) scales and biomarkers. In addition to this osteoporosis study, hemophilic arthropathy of the knee with respect to loss of knee cartilage will also be explored by using magnetic resonance imaging (MRI substudy). No investigational product will be dispensed.
Status | Terminated |
Enrollment | 3 |
Est. completion date | April 13, 2012 |
Est. primary completion date | April 13, 2012 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 25 Years and older |
Eligibility | Inclusion Criteria: - Male and at least 25 years old at the time of screening - Moderately severe or severe hemophilia A or B (factor VIII or factor IX <= 2% by chart documentation) - Ambulatory (ie, not wheel chair dependent) - Performance status - ECOG of 0 or 1 (= out of bed at least 75% of time) - Willing and able to comply with the requirements of the protocol and is able to give informed consent Additional inclusion criteria for MRI Substudy: - Baseline knee joint space width is >= 3mm at the medial or lateral aspect of either knee as measured by weightbearing fixed flexion PA X-ray - Able to undergo 1.5 or 3T MRI Exclusion Criteria: - Inability to position properly for DXA - Presence of orthopedic hardware or other artifact in the lumbar spine (L1-L4) or either proximal femur - Prior documentation of being HIV positive - Radiosynovectomy or surgical synovectomy within the last 6 months - Current or past treatment with bone active drugs - Long-term corticosteroid use [defined as 7.5-mg prednisone daily (or equivalent) for >= 3 months] - If subject is family member or employee of the investigator Additional exclusion criteria for MRI Substudy: - Any contraindication or relative contraindication to MRI - Less than 3mm knee joint space width at the medial and lateral aspect of both knees on baseline X-ray evaluation - Knee bleed within 30 days of informed consent - Prior total knee arthroplasty (TKA) |
Country | Name | City | State |
---|---|---|---|
United States | Los Angeles Orthopedic Hospital | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Baxalta now part of Shire |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline Endpoint: Z-Score by dual-energy X-ray absorptiometry (DXA) at baseline | Baseline | ||
Primary | Longitudinal Endpoint: Change in bone mineral density by DXA over 2 years | 2 years | ||
Primary | Longitudinal Endpoint: Rate of loss of knee cartilage parameters over 2 years by MRI | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03834727 -
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
|
||
Completed |
NCT03191799 -
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
|
Phase 3 | |
Completed |
NCT01599819 -
BAX 855 Dose-Escalation Safety Study
|
Phase 1 | |
Terminated |
NCT04541628 -
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
|
Phase 1/Phase 2 | |
Completed |
NCT02847637 -
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
|
Phase 3 | |
Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
Completed |
NCT04085458 -
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
|
Phase 4 | |
Completed |
NCT04565236 -
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
|
Phase 4 | |
Recruiting |
NCT05987449 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
Not yet recruiting |
NCT02888223 -
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
|
Phase 1 | |
Completed |
NCT02528968 -
National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
|
N/A | |
Completed |
NCT02225483 -
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
|
N/A | |
Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
Terminated |
NCT00995046 -
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
|
N/A | |
Completed |
NCT00868530 -
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
|
Phase 3 | |
Completed |
NCT00839202 -
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
|
N/A | |
Completed |
NCT00629837 -
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
|
Phase 1 |